Ora Biomedical
About Ora Biomedical
Ora Biomedical develops small molecule therapeutics that target the molecular mechanisms of aging to extend lifespan and delay chronic illnesses. Utilizing a high-throughput robotics platform and AI-based data analysis, the company conducts extensive preclinical drug screening to identify effective gerotherapeutics for age-related diseases.
```xml <problem> Aging is the primary risk factor for many chronic diseases, leading to a decline in healthspan and lifespan. Traditional drug discovery methods are slow and inefficient in identifying interventions that target the fundamental mechanisms of aging. </problem> <solution> Ora Biomedical utilizes a high-throughput screening platform, WormBot-AI, to identify small molecule therapeutics that modulate the aging process and extend healthy lifespan. The platform combines automated robotics with AI-driven data analysis to screen interventions in _C. elegans_, measuring health and survival across numerous populations simultaneously. By focusing on evolutionarily conserved aging mechanisms, Ora Biomedical aims to discover broad-acting gerotherapeutics applicable to both age-related and rare diseases. These interventions are then validated in mammalian models, paving the way for clinical development and preventative medicine strategies. </solution> <features> - WormBot-AI: A high-throughput robotics platform for preclinical drug screening in _C. elegans_. - AI-based data analysis: State-of-the-art algorithms for measuring health and survival metrics. - Small molecule and natural product analysis: Unbiased compound screening to identify novel interventions. - Normative aging and disease models: Analysis of lifespan and healthspan measures, including age-associated movement and behavior changes. - Mechanistic and translational validation studies: Characterization of drug targets using genetic, biochemical, and multi-omic approaches. </features> <target_audience> Ora Biomedical partners with academic and commercial clients interested in evaluating novel therapies and accelerating their drug discovery pipeline. </target_audience> ```
What does Ora Biomedical do?
Ora Biomedical develops small molecule therapeutics that target the molecular mechanisms of aging to extend lifespan and delay chronic illnesses. Utilizing a high-throughput robotics platform and AI-based data analysis, the company conducts extensive preclinical drug screening to identify effective gerotherapeutics for age-related diseases.
Where is Ora Biomedical located?
Ora Biomedical is based in Seattle, United States.
When was Ora Biomedical founded?
Ora Biomedical was founded in 2022.
How much funding has Ora Biomedical raised?
Ora Biomedical has raised 720000.
Who founded Ora Biomedical?
Ora Biomedical was founded by Mitchell Lee.
- Mitchell Lee - CEO/Co-Founder
- Location
- Seattle, United States
- Founded
- 2022
- Funding
- 720000
- Employees
- 6 employees